Top Markets
#1 MowCat MowCat +49.01%
#2 Derive Derive +24.21%
#3 Audiera Audiera +19.54%
#4 Geodnet Geodnet +16.54%
#5 aPriori aPriori +15.50%
#6 Biconomy Biconomy +14.76%
#7 Cross Cross +14.26%
#8 Humanity Humanity +12.39%
#9 Quack AI Quack AI +11.55%
#10 Palladium Network Palladium Network +10.79%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Clearmind Medicine Inc. Clearmind Medicine Inc.

Clearmind Medicine Inc.

CMND
Rank in Stocks #35565
Operating as a pre-clinical pharmaceutical firm, Clearmind Medicine Inc.... Operating as a pre-clinical pharmaceutical firm, Clearmind Medicine Inc. specializes in pioneering psychedelic therapies aimed at addressing overlooked medical conditions. Its development efforts encompass treatments for alcohol use disorders, notably binge drinking, various eating disorders, depression, and a spectrum of mental health challenges including binge eating and other compulsive behaviors. Founded in 2017, this Vancouver, Canada-based entity transitioned from its former identity as Cyntar Ventures Inc. to Clearmind Medicine Inc. in March 2021.
Share Price
$1.17
Last synced: 2024-03-14
Market Cap
$3.72M
Change (1 day)
-13.55%
Change (1 year)
0.00%
Country
CA
Trade Clearmind Medicine Inc. (CMND)

Category

Healthcare
P/E ratio for Clearmind Medicine Inc. (CMND)
P/E ratio as of 2026 TTM: 0
According to Clearmind Medicine Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Clearmind Medicine Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.